Shih Austin, Hsu Chih-Yuan, Shyr Yu
Department of Mathematics, Vanderbilt University, Nashville, TN, USA.
Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
Res Sq. 2024 Dec 12:rs.3.rs-5418253. doi: 10.21203/rs.3.rs-5418253/v1.
Difference in Restricted Mean Survival Time (DRMST) has attracted attention and is increasingly used in non-inferiority (NI) trials because of its superior power in detecting treatment effects compared to hazard ratio. However, when treatment switching (also known as crossover) occurs, the widely used intention-to-treat (ITT) analysis can underpower or overpower NI trials.
We propose a simulation-based approach, named , to calculate powers and determine the necessary sample size to achieve a desired power for non-inferiority trials that allow treatment switching, in ITT analysis using DRMST.
Real-world and simulated examples are used to illustrate the proposed method and examine how switching probability, switching time, the relative effectiveness of treatments, allocation ratio, and even time distribution influence powers and sample sizes. Our simulation study shows that switching time and switching probability decrease or increase powers and sample sizes compared to those in the scenarios without treatment switching. A shorter switching time and a higher switching probability amplify the magnitude of these changes. The direction of the change in powers and sample sizes depends on the relative effectiveness of the treatments. When , power decreases and sample size increases, while leads to the opposite effect, where and are the median survivals in the control and experimental groups, respectively.
This simulation-based approach offers a preview of how treatment switching can influence powers and sample sizes in NI trials, providing investigators with useful information before conducting the trials. is freely available at https://github.com/cyhsuTN/nifts.
受限平均生存时间差异(DRMST)已引起关注,并且由于其在检测治疗效果方面比风险比具有更强的功效,因此越来越多地用于非劣效性(NI)试验。然而,当发生治疗转换(也称为交叉)时,广泛使用的意向性分析(ITT)可能会使NI试验的功效不足或功效过强。
我们提出了一种基于模拟的方法,名为 ,用于在使用DRMST的ITT分析中,计算允许治疗转换的非劣效性试验的功效,并确定达到所需功效所需的样本量。
使用实际案例和模拟示例来说明所提出的方法,并研究转换概率、转换时间、治疗的相对有效性、分配比例以及时间分布如何影响功效和样本量。我们的模拟研究表明,与没有治疗转换的情况相比,转换时间和转换概率会降低或增加功效和样本量。较短的转换时间和较高的转换概率会放大这些变化的幅度。功效和样本量变化的方向取决于治疗的相对有效性。当 时,功效降低而样本量增加,而 则会产生相反的效果,其中 和 分别是对照组和实验组的中位生存期。
这种基于模拟的方法提供了治疗转换如何影响NI试验的功效和样本量的预览,在进行试验之前为研究人员提供有用的信息。 可在https://github.com/cyhsuTN/nifts上免费获取。